|451.90||-1.10||-0.24%||Vol 62.19K||1Y Perf 25.94%|
|Jun 9th, 2023 10:49 DELAYED|
|-0.86 -0.19%||- -|
|Target Price||476.88||Analyst Rating||Strong Buy 1.50|
|Potential %||5.11||Finscreener Ranking||★ 40.96|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||+ 35.59|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★★ 59.21|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||67.85||Earnings Rating||Neutral|
|Market Cap||37.51B||Earnings Date||1st Aug 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||1st Aug 2023|
|Estimated EPS Next Report||2.43|
|EPS Growth Next 5 Years %||17.30|
|Avg. Weekly Volume||405.38K|
|Avg. Monthly Volume||365.71K|
|Avg. Quarterly Volume||379.66K|
IDEXX Laboratories Inc. (NASDAQ: IDXX) stock closed at 453 per share at the end of the most recent trading day (a 0.51% change compared to the prior day closing price) with a volume of 378.80K shares and market capitalization of 37.51B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 9300 people. IDEXX Laboratories Inc. CEO is Jonathan J. Mazelsky.
The one-year performance of IDEXX Laboratories Inc. stock is 25.94%, while year-to-date (YTD) performance is 11.04%. IDXX stock has a five-year performance of 106.17%. Its 52-week range is between 317.06 and 515.79, which gives IDXX stock a 52-week price range ratio of 67.85%
IDEXX Laboratories Inc. currently has a PE ratio of 56.90, a price-to-book (PB) ratio of 77.91, a price-to-sale (PS) ratio of 14.62, a price to cashflow ratio of 65.80, a PEG ratio of 2.32, a ROA of 28.73%, a ROC of 37.61% and a ROE of 120.08%. The company’s profit margin is 19.97%, its EBITDA margin is 29.40%, and its revenue ttm is $2.54 Billion , which makes it $30.66 revenue per share.
Of the last four earnings reports from IDEXX Laboratories Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.43 for the next earnings report. IDEXX Laboratories Inc.’s next earnings report date is 01st Aug 2023.
The consensus rating of Wall Street analysts for IDEXX Laboratories Inc. is Strong Buy (1.5), with a target price of $476.88, which is +5.11% compared to the current price. The earnings rating for IDEXX Laboratories Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
IDEXX Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
IDEXX Laboratories Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.64, ATR14 : 11.80, CCI20 : -107.76, Chaikin Money Flow : -0.01, MACD : -7.00, Money Flow Index : 39.09, ROC : -6.84, RSI : 37.44, STOCH (14,3) : 12.64, STOCH RSI : 0.18, UO : 48.48, Williams %R : -87.36), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of IDEXX Laboratories Inc. in the last 12-months were: Brian P. Mckeon (Option Excercise at a value of $0), Daniel M. Junius (Option Excercise at a value of $940 091), Daniel M. Junius (Sold 5 233 shares of value $2 413 318 ), James F. Polewaczyk (Option Excercise at a value of $0), Jonathan J. Mazelsky (Option Excercise at a value of $2 425 980), Jonathan J. Mazelsky (Sold 23 730 shares of value $9 622 228 ), Kathy V. Turner (Option Excercise at a value of $3 290 219), Kathy V. Turner (Sold 17 887 shares of value $7 944 792 ), Lane Michael (Sold 0 shares of value $0 ), M. Anne Szostak (Option Excercise at a value of $320 560), M. Anne Szostak (Sold 740 shares of value $317 127 ), Martin Alexander Smith (Sold 0 shares of value $0 ), Mazelsky Jonathan (Sold 0 shares of value $0 ), Mckeon Brian (Sold 0 shares of value $0 ), Michael J. Lane (Option Excercise at a value of $0), Nimrata Hunt (Option Excercise at a value of $99 970), Polewaczyk James (Sold 0 shares of value $0 ), Sharon E. Underberg (Option Excercise at a value of $0), Tina Hunt (Sold 0 shares of value $0 ), Turner Kathy (Sold 1 000 shares of value $-239 415 ), Turner Kathy (Sold 4 010 shares of value $2 029 413 ), Underberg Sharon (Sold 0 shares of value $0 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Moderate Buy|
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
CEO: Jonathan J. Mazelsky
Telephone: +1 207 556-0300
Address: One IDEXX Drive, Westbrook 04092, ME, US
Number of employees: 9 300
Wed, 03 May 2023 03:05 GMT Idexx Laboratories (IDXX) Gets a Buy from Goldman Sachs- TipRanks. All rights reserved.
Tue, 07 Feb 2023 11:40 GMT Analysts Offer Insights on Healthcare Companies: Cigna (CI), Idexx Laboratories (IDXX) and Lyra Therapeutics (LYRA)- TipRanks. All rights reserved.
Tue, 07 Feb 2023 11:30 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and aTyr Pharma (LIFE)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.